Company intelligence / Profile preview
Corium
Grand Rapids, Michigan, United Statescorium.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Corium has successfully developed and received FDA approval for two CNS products: ADLARITY® (donepezil transdermal system) for Alzheimer's disease and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) for ADHD[7][8].
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculestransdermal drug delivery systemsoral thin films
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lotus Pharmaceutical (for ADLARITY in Asian markets)[8]KemPharm[10]
Beyond the preview
Go deeper on Corium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Corium.